(Q42782242)

7 November 2017

title

HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations (English)

1 reference

7 November 2017

1 reference

2

1 reference

7 November 2017

3

Karel Ulbrich

0 references

Wim Hennink

6

object named as

Wim E Hennink

1 reference

7 November 2017

1

Twan Lammers

1 reference

7 November 2017

7

Gert Storm

1 reference

7 November 2017

Karel Ulbrich

3

1 reference

7 November 2017

Peter Peschke

4

1 reference

7 November 2017

Peter E Huber

5

1 reference

7 November 2017

Fabian Kiessling

8

1 reference

7 November 2017

publication date

1 December 2010

1 reference

7 November 2017

1 reference

7 November 2017

volume

5

1 reference

7 November 2017

issue

10

1 reference

7 November 2017

page(s)

1501-1523

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

7 November 2017

1 reference

Drug delivery systems: entering the mainstream

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Nanocarriers as an emerging platform for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Nanoparticle therapeutics: an emerging treatment modality for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Tumour-targeted nanomedicines: principles and practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Ligand-targeted therapeutics in anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Chemical approaches to triggerable lipid vesicles for drug and gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

A review of stimuli-responsive nanocarriers for drug and gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Multifunctional and stimuli-sensitive pharmaceutical nanocarriers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Present and future applications of biomaterials in controlled drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Hydrogels in pharmaceutical formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Hydrogels for biomedical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Liposomal encapsulated anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Recent advances with liposomes as pharmaceutical carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Water soluble polymers in tumor targeted delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Polymer conjugates as anticancer nanomedicines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

HPMA copolymers: 30 years of advances.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Synthesis and characterization of HE-24.8: a polymeric contrast agent for magnetic resonance angiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

The concurrent chemoradiation paradigm--general principles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Effect of ionizing radiation on AP-1 binding activity and basic fibroblast growth factor gene expression in drug-sensitive human breast carcinoma MCF-7 and multidrug-resistant MCF-7/ADR cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Determinants of drug delivery and transport to solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Radiation-induced apoptosis in microvascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Polymer therapeutics designed for a combination therapy of hormone-dependent cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

HPMA copolymers: origins, early developments, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Targeted therapy of cancer: new prospects for antibodies and immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Shifting emphasis from pharmacogenomics to theragnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

Magnetic nanoparticles for theragnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.10.130

21 January 2018

Identifiers

DOI

10.2217/NNM.10.130

1 reference

7 November 2017

1 reference